Shares of GlaxoSmithKline plc (NYSE:GSK) have earned a consensus rating of “Hold” from the twenty-one analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $42.50.
Several research firms recently issued reports on GSK. UBS Group cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, Zacks Investment Research upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Monday, February 4th.
Shares of GSK stock traded up $0.19 during trading hours on Monday, hitting $40.18. 1,701,862 shares of the company’s stock were exchanged, compared to its average volume of 2,465,125. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72. The stock has a market capitalization of $99.67 billion, a PE ratio of 12.72, a PEG ratio of 2.07 and a beta of 0.74. GlaxoSmithKline has a 52 week low of $36.41 and a 52 week high of $42.36.
The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.4953 dividend. This represents a $1.98 annualized dividend and a yield of 4.93%. The ex-dividend date of this dividend is Thursday, May 16th. GlaxoSmithKline’s payout ratio is 61.71%.
In related news, Director Plc Glaxosmithkline bought 325,000 shares of the business’s stock in a transaction on Monday, April 22nd. The shares were purchased at an average price of $18.00 per share, with a total value of $5,850,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Princeton Global Asset Management LLC acquired a new stake in shares of GlaxoSmithKline during the first quarter worth about $37,000. Rehmann Capital Advisory Group raised its position in shares of GlaxoSmithKline by 46.5% during the first quarter. Rehmann Capital Advisory Group now owns 4,066 shares of the pharmaceutical company’s stock worth $170,000 after purchasing an additional 1,290 shares during the period. GYL Financial Synergies LLC acquired a new stake in shares of GlaxoSmithKline during the first quarter worth about $1,826,000. Columbia Asset Management raised its position in shares of GlaxoSmithKline by 11.9% during the first quarter. Columbia Asset Management now owns 20,548 shares of the pharmaceutical company’s stock worth $1,300,000 after purchasing an additional 2,185 shares during the period. Finally, M Holdings Securities Inc. raised its position in shares of GlaxoSmithKline by 26.1% during the first quarter. M Holdings Securities Inc. now owns 9,557 shares of the pharmaceutical company’s stock worth $399,000 after purchasing an additional 1,978 shares during the period. 11.28% of the stock is currently owned by hedge funds and other institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Percentage Decliners
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.